Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $12.6 million.

  • Ironwood Pharmaceuticals' Gains from Investment Securities was N/A to -$7,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year change of. This contributed to the annual value of $12.6 million for FY2024, which is 116.00% up from last year.
  • Ironwood Pharmaceuticals' Gains from Investment Securities amounted to $12.6 million in FY2024, which was up 116.00% from $5.8 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Gains from Investment Securities ranged from a high of $13.5 million in FY2020 and a low of $5.8 million during FY2023.
  • For the 3-year period, Ironwood Pharmaceuticals' Gains from Investment Securities averaged around $8.5 million, with its median value being $6.9 million (2022).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first tumbled by 30.36% in 2021, then spiked by 116.00% in 2024.
  • Ironwood Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $13.5 million in 2020, then plummeted by 30.36% to $9.4 million in 2021, then fell by 26.05% to $6.9 million in 2022, then decreased by 15.80% to $5.8 million in 2023, then surged by 116.00% to $12.6 million in 2024.